.Nature Medicine, Posted online: 09 Oct 2024 doi:10.1038/ s41591-024-03316-9Delandistrogene moxeparvovec obtained FDA authorization after a negative trial, which highlights the numerous intricacies and obstacles of medication development within this setting.